Viatris Inc
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
1000 MYLAN BOULEVARD, CANONSBURG, PA, 15317
Mailing Address
1000 MYLAN BOULEVARD, CANONSBURG, PA, 15317
Phone
(724) 514-1465
Fiscal Year End
1231
EIN
834364296
Financial Overview
FY2025 FY
$15.43B
Revenue
$22.48B
Total Liabilities
$0.05
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
Annual Reports
10-K
February 26, 2026
- Successfully generated $2 billion in cash from divestitures in 2024, with planned sales of OTC ($2B) and API ($1B) businesses by late 2025.
- Strategically acquired late-stage assets from Idorsia Pharmaceuticals for $100 million upfront, bolstering future specialty pipeline in hypertension and insomnia.
Insider Trading
SELL
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.